While the pharmaceutical industry changes every day with new drug approvals, patent expirations, and blockbuster launches shifting the leaderboard of the biggest drugmakers around the globe, there are always some big names that stay atop the list.
For example, 2025 brought a fresh start for many of these top drugmakers as they benefited from new GLP-1 drugs for diabetes and weight-loss — and decades-old oncology and immunology franchises continued to generate tens of billions of dollars reliably.
Here’s our comprehensive guide to all ten of the world’s largest pharmaceutical companies based on pharmaceutical sales revenue. We’ll break down everything you need to know about each company, including what they do best, why their work matters both to patients and to investors, and the evolution of the entire industry itself.
Quick-Reference: Top 10 Pharma Companies by Revenue
| Rank | Company | Headquarters | 2025 Pharma Revenue | Best Known For |
|---|---|---|---|---|
| 1 | Johnson & Johnson | United States | ~$86.9B | Oncology (Darzalex), immunology, broad portfolio |
| 2 | Eli Lilly | United States | ~$65.2B | Mounjaro, Zepbound; fastest-growing major pharma |
| 3 | Pfizer | United States | ~$62.6B | Vaccines, oncology, Eliquis |
| 4 | Merck & Co. | United States | ~$58.1B | Keytruda oncology franchise |
| 5 | Roche | Switzerland | ~$57.6B | Oncology, diagnostics, Ocrevus |
| 6 | AbbVie | United States | ~$61.2B | Skyrizi, Rinvoq immunology |
| 7 | AstraZeneca | United Kingdom | ~$58.7B | Oncology, respiratory, rare disease |
| 8 | Novartis | Switzerland | ~$54.5B | Cardiovascular, gene therapy |
| 9 | Sanofi | France | ~$47.4B | Vaccines, immunology, rare disease |
| 10 | Bristol Myers Squibb | United States | ~$48.2B | Oncology, hematology, immunology |
Figures reflect full-year 2025 pharmaceutical segment revenue as reported in company annual filings, converted to U.S. dollars where necessary. Rankings shift slightly depending on whether total company revenue or pharma-only revenue is used.
1. Johnson & Johnson
Johnson & Johnson remained on top of the pharmaceutical revenue charts again this year with innovative medicine’s division hitting a big milestone as well. Driven mostly by its oncology portfolio, its Darzalex (multiple myeloma treatment) still saw double-digit growth while other newcomers like Carvykti and Rybrevant also saw good momentum in sales.
This diversity that J&J maintains within the market helps protect them from things like the onslaught of patents expiring which would leave some companies struggling but in this case, they have more than a dozen brands seeing double-digit growth across areas such as oncology, immunology and neuroscience among others.
2. Eli Lilly
The story behind this success was mostly the meteoric growth in sales of two key products — Mounjaro (a drug used to treat diabetes) and Zepbound (used to treat obesity). Both are part of a class called GLP 1 drugs that help control blood glucose levels through various mechanisms. In turn, these drugs made Eli Lilly’s revenues grow at double digit rates year-over-year, leading to its stock market cap reaching $1tn – the first time a healthcare company reached such lofty heights in terms of valuation.
The question is how big the demand actually is? Data saya that “the number of patient requests for Zepbound has gotten to the point where it is a central consideration when determining what inventory to stock”, saying it was as important as insulins were in previous decades. While one cannot attribute all of the growth solely to culture shifts (this can only happen if people are also buying more), it helps explain why the math makes sense.
3. Pfizer
The fortunes made by drugmakers during the pandemic were fueled by selling covid-19 vaccines and treatments. Revenue from those products dropped as pandemics receded over the past two years—so did Pfizer’s. Instead, the company is leaning more heavily on other areas where it does well: oncology (including its flagship cancer drug Padcev), sales of its blockbuster blood thinner Eliquis and growth of its biosimilars business.
In many ways, the pharma giant’s experience provides an important lesson about building a lasting business—not just for companies in the healthcare sector, but all businesses. It’s easy to get carried away after making a lot of money. But long-term success depends on having the wherewithal to build infrastructure once the euphoria wanes. In Pfizer’s case, this means oncology research and development, and setting up biosimilar manufacturing facilities.
4. Merck & Co.
At its core, Merck’s success has always rested on just one drug: Keytruda, its flagship cancer immunotherapy therapy. And while Keytruda continues to grow as an early stage cancer treatment for additional tumor types, generating billions of dollars in quarterly revenues every year — we’re going to spend more time talking about how this happens — there’s also an obvious downside to all of that growth.
That key drug’s patent expires later this decade, leaving Merck with little choice but to find its next big hit in the coming years. And if it can’t or doesn’t have enough R&D investment behind it then things could get bad pretty fast.
5. Roche
Pharmaceutical giants usually produce drugs but Roche does more than that. It is also one of the biggest diagnostics companies in the world. In fact, if you look closely, you’ll find that some of the best-known medicines made today are products from Roche such as Ocrevus for multiple sclerosis or Vabysmo to treat eye disease. But there are also tests and other types of companion diagnostics designed to enable what we call “precision medicine.”
The company has spent considerable efforts investing in artificial intelligence-assisted oncology tools via its Flatiron Health subsidiary, too, which makes it easy to see why it sits at the confluence where software and biology intersect (rather than merely chemistry).
6. AbbVie
When AbbVie’s biggest-selling drug, Humira, lost its exclusivity earlier this year, the company was facing what would be one of the steepest patent cliffs in pharma history. But thanks to rapid growth from its Skyzi and Rinvoq immunology drugs, AbbVie managed to more than make up for Humira’s loss.
The lesson here is an important one to remember for people who think that losing patent protection means automatic death for a pharmaceutical company. With the right pipeline investments made well in advance, companies are able to swap out their old blockbuster products for two brand new ones..l
7. AstraZeneca
AstraZeneca’s portfolio includes everything from oncology (which remains a huge focus) through cardiovascular/metabolic disease, respiratory conditions to rare diseases making the business less susceptible to the vagaries of specific therapy areas. But perhaps even more crucially, AstraZeneca has been far more aggressive in growing its presence in emerging markets compared with most rivals as this area represents increasing opportunity for future pharma growth.
8. Novartis
Over recent years, Novartis has been focusing more and more on just those types of innovations, including in fields such as cardiovascular care and gene therapy — where some treatments may eliminate the need for lifelong drug regimens. And while this strategy involves taking big bets by narrowing their scope and abandoning some generic and consumer health business lines, Novartis believes the risk pays off handsomely.
After all, isn’t there an old saying about concentrating your efforts? This means, wouldn’t it be better off being really good at fewer things than merely OK at a lot more?
9. Sanofi
Nowhere was Sanofi’s size on display more than with its vaccine business, which continues to be one of the largest in the world alongside an expanding immunology and rare disease portfolio. The company was also putting money into emerging technologies such as mRNA vaccines (a sector that most other competitors sprinted ahead in amid the frenzy over developing coronavirus vaccines).
It wasn’t always news headlines for Sanofi, but rather consistent performance in all corners of its vaccine and specialty portfolio, even if it didn’t break through to massive sales, that proved its strength.
10. Bristol Myers Squibb
Rounding out the top ten, Bristol Myers Squibb has built strength in oncology and hematology, with a growing immunology division as well. The company has navigated patent expirations on older products by acquiring and scaling newer therapies, a strategy increasingly common across the industry.
Bristol Myers Squibb’s position shows that being in the top ten doesn’t require being the biggest in any one category. Consistent performance across several therapeutic areas is enough to secure a lasting place on this list.
What This Ranking Really Tells Us
A few patterns stand out across this list:
- Oncology is the single biggest growth driver across nearly every major pharma company.
- GLP-1 drugs for diabetes and obesity have created the fastest revenue growth the industry has seen in decades.
- Patent cliffs are inevitable, but companies that invest early in their next-generation pipeline can offset the loss.
- Diversification across therapeutic areas tends to produce steadier, more resilient revenue than reliance on a single blockbuster.
None of these companies got to the top by accident. Each represents years, sometimes decades, of R&D investment that may not pay off for a long time, if ever. That patience is part of what makes the pharmaceutical industry unlike almost any other.
Where Do Indian Pharma Companies Fit In?
None of the ten companies listed here have their headquarters located in India. However, it’s important to recognize the country’s critical role as the world’s largest supplier of generic medicines by volume with its leading companies (Sun Pharma, Dr. Reddy’s, Cipla, Aurobindo Pharma etc.) supplying significant quantities of generic medicine into the U.S., Africa and Southeast Asia markets.
Though these Indian companies generate significantly lower revenues ($10-30 billion) vs. the $250B+ generating global leaders featured above, they play a huge part in enabling widespread access to life-saving antibiotics and antiretrovirals around the world. If you’re receiving any of these drugs today, there’s a good chance your medication was made in India. That said, though Indian pharmaceutical firms will continue to grow globally through investments in developing biosimilars/specialty generics, they won’t be displacing the top 10 players anytime soon.
Frequently Asked Questions
Which is the largest pharmaceutical company in the world?
Johnson & Johnson currently holds the top spot by pharmaceutical revenue, though Eli Lilly leads by market capitalization thanks to the rapid growth of its GLP-1 drugs.
How is this ranking calculated?
This list ranks companies by pharmaceutical (drug and vaccine) sales revenue reported in official 2025 annual filings, rather than total company revenue, which can include unrelated business segments like medical devices or consumer health products.
Does this list change often?
Yes. Quarterly earnings, new drug approvals, and patent expirations can shift rankings meaningfully from one year to the next, which is why it’s worth checking updated figures each year rather than relying on older lists.
Why isn’t any Indian or Chinese pharma company in the top 10?
Companies like Sun Pharma and Sinopharm generate substantial revenue, but Sinopharm is primarily a state-owned distributor rather than an R&D-driven drugmaker, and Indian firms focus heavily on generics, which carry much lower prices than the patented, branded medicines that drive revenue for companies like Pfizer or Merck. Volume leadership doesn’t always translate into revenue leadership.
What is the difference between pharma revenue and total company revenue?
Total company revenue can include unrelated business lines such as medical devices, diagnostics, or consumer health products. Pharma revenue isolates sales from prescription drugs and vaccines only, which is why some companies rank differently depending on which figure is used.
